INHIBIKASE THERAPEUTICS INC (IKT)
US45719W2052 - Common Stock
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – ...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension...
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the fourth quart...
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET...
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate...
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -...
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of...
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - -...